Because it's far too early in the game to make any real assessment of toxicity. If it kills cancer cells but kills the patient then it's no good is it? Soaking cancer cells in a lab in sulphuric acid probably kills them but I'm not going to inject it into a patient. SYNTA's trials are very early stage
The key to successful biotech investing is to get in early and de-risk any downside. You have seen a very nasty correction recently; and I think only the strong will survive (meaning gettting margin calls and so forth). If anything; Ganetespib has an incredible safety profile...so thats called major de-risking and investing in a good long term stock as the trials results are beginning to show some success.
Once Ganetespib starts showing success in other indications and hire a solid CEO...you might be pleasantly surprised just how high this major Oncology company goes...and if a Partnership occurs...Roth's $27 target will be reached rather easily.